Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Cancer Res. 2010 Feb 16;70(5):1960–1969. doi: 10.1158/0008-5472.CAN-09-3535

Figure 1.

Figure 1

Obatoclax has single agent activity against cholangiocarcinoma which is not associated with altered BCL-2 protein expression (A,B) Cell death was quantified by clonogenic assay (A) in four cholangiocarcinoma cell lines (HuCCT-1, Mz-ChA-1, BDEneu, KMCH-1) treated with obatoclax at doses ranging from 0 to 800 nM for 48 h. Results are colony forming units as a percentage of control and represent means from three separate trials. (B) Immunoblotting of three obatoclax-sensitive cholangiocarcinoma cell lines treated with vehicle or increasing doses of obatoclax (100nM-400nM) for 24 hours. (*) No commercially available antibody for rat Mcl-1.